News
Consolidated sales amounted to €2,044 million in the first-half of 2025 from €1,902 million in the prior year period, a +9.4% like-for-like growth.
Swipe to discover more
-
bioMérieux receives U.S. FDA 510(k) clearance and CLIA-waiver for Anterior Nasal Swab specimens, an additional sample type for use with the BIOFIRE® SPOTFIRE® R/ST Panel Mini
bioMérieux today announces that its BIOFIRE® SPOTFIRE® R/ST Panel Mini has received U.S. FDA 510(k) clearance and CLIA waiver for the addition of Anterior Nasal Swab as a validated specimen type for this panel. -
« Always consider sepsis in the context of infection. »
Patient associations across the globe are actively engaged in promoting this critical message to both healthcare professionals and the broader public. We met with Dr Rafael Moraes from ILAS, Melissa Mead from The UK Sepsis Trust and Thomas Heymann from Sepsis Alliance to learn more about their actions. -
bioMérieux and Moderna Collaborate to Advance individualized Cancer Therapies
bioMérieux has a long history of collaboration with Moderna, a biotechnology company that gained worldwide recognition during the COVID-19 pandemic for its rapid development of a mRNA-based vaccine. Today, this partnership is helping accelerate the development of individualized cancer treatments.
Enabling Decision-Making
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19